QR kód

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Abstract Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; dat...

Celý popis

Uloženo v:
Hlavní autoři: Peter Nash, Laura C. Coates, Alan J. Kivitz, Philip J. Mease, Dafna D. Gladman, José A. Covarrubias-Cobos, Oliver FitzGerald, Dona Fleishaker, Cunshan Wang, Joseph Wu, Ming-Ann Hsu, Sujatha Menon, Lara Fallon, Ana Belén Romero, Keith S. Kanik
Médium: Artigo
Jazyk:Inglês
Vydáno: Adis, Springer Healthcare 2020-06-01
Edice:Rheumatology and Therapy
Témata:
Long-term extension
Psoriatic arthritis
Tofacitinib
On-line přístup:https://doi.org/10.1007/s40744-020-00209-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky